Quotes 5-day view End-of-day quote Shenzhen Stock Exchange
06/30/2022
07/01/2022
07/04/2022
07/05/2022
07/06/2022
Date
114.45
115.3
121.89
126.51
127.45
Last
7021555
4896822
11187310
9492627
12653800
Volume
+3.11%
+0.74%
+5.72%
+3.79%
+0.74%
Change
Estimated financial data (e) CNY USD
Sales 2022
7 013 M
1 045 M
1 045 M
Net income 2022
2 937 M
438 M
438 M
Net cash position 2022
11 798 M
1 759 M
1 759 M
P/E ratio 2022
37,8x
Yield 2022
0,53%
Sales 2023
8 950 M
1 334 M
1 334 M
Net income 2023
3 657 M
545 M
545 M
Net cash position 2023
14 024 M
2 091 M
2 091 M
P/E ratio 2023
30,4x
Yield 2023
0,63%
Capitalization
106 B
15 729 M
15 729 M
EV / Sales 2022
13,4x
EV / Sales 2023
10,2x
Nbr of Employees
-
Free-Float
68,5%
Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows:
- provision of clinical trial services and related technological services (51.8%);
- provision of clinical research consulting services (48.2%).
Ratings of Hangzhou Tigermed Consulting Co., Ltd
All news about HANGZHOU TIGERMED CONSULTING CO., LTD
07/04 Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced.. CI
06/27 Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes CI
05/25 Hangzhou Tigermed Consulting Co., Ltd Announces 2021 Final Profit Distribution Plan to .. CI
05/20 Hangzhou Tigermed Consulting Co., Ltd Approves Final Dividend to for the Year Ended Dec.. CI
04/28 Hangzhou Tigermed Consulting Co. Ltd. Announces Ordinary Final Dividend for the Year En.. CI
04/27 Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$115.13 From HK$134.75,.. MT
04/27 Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to 125.87 Yuan From 147.33 Y.. MT
04/26 Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter En.. CI
04/07 LTZ Therapeutics announced that it has received $17 million in funding from K2VC, Qimin.. CI
04/01 Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced.. CI
03/28 Hangzhou Tigermed Consulting Co., Ltd Proposes Final Ordinary Dividend for the Year End.. CI
03/14 Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$134.75 From HK$141.67,.. MT
03/14 Nomura Adjusts Tigermed's Price Target to 147.33 Yuan From 154.89 Yuan, Keeps at Buy MT
03/11 Hangzhou Tigermed Logs Higher Preliminary Earnings in 2021; Shenzhen Shares Jump 4% MT
03/10 Hangzhou Tigermed Posts Over 100% Surge in Preliminary January-February Revenue; Shenzh.. MT
News in other languages on HANGZHOU TIGERMED CONSULTING CO., LTD
Analyst Recommendations on HANGZHOU TIGERMED CONSULTING CO., LTD
Chart HANGZHOU TIGERMED CONSULTING CO., LTD
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends HANGZHOU TIGERMED CONSULTING CO., LTD
Short Term Mid-Term Long Term Trends Bullish Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
20
Last Close Price
127,45 CNY
Average target price
147,13 CNY
Spread / Average Target
15,4%
Please enable JavaScript in your browser's settings to use dynamic charts.